PARP Inhibitor Efficacy Depends on CD8
BRCA1 Protein
/ deficiency
BRCA2 Protein
/ deficiency
Biomarkers
CD8-Positive T-Lymphocytes
/ drug effects
Female
Humans
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating
/ immunology
Membrane Proteins
/ metabolism
Poly(ADP-ribose) Polymerase Inhibitors
/ pharmacology
Signal Transduction
/ drug effects
Triple Negative Breast Neoplasms
/ drug therapy
Tumor Microenvironment
/ drug effects
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
15
10
2018
revised:
12
04
2019
accepted:
18
04
2019
pubmed:
25
4
2019
medline:
9
7
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8
Identifiants
pubmed: 31015319
pii: 2159-8290.CD-18-1218
doi: 10.1158/2159-8290.CD-18-1218
pmc: PMC6548644
mid: NIHMS1527923
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
Biomarkers
0
Membrane Proteins
0
Poly(ADP-ribose) Polymerase Inhibitors
0
STING1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
722-737Subventions
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA090687
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226776
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
J Biol Chem. 2003 Mar 14;278(11):9441-7
pubmed: 12524442
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6
pubmed: 17626182
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
pubmed: 20877296
Clin Cancer Res. 2011 May 1;17(9):2619-27
pubmed: 21372217
Breast Cancer Res Treat. 2012 Apr;132(3):793-805
pubmed: 21562709
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9378-83
pubmed: 22619329
Cancer Discov. 2013 Jan;3(1):68-81
pubmed: 23103855
Clin Cancer Res. 2013 Jan 15;19(2):336-46
pubmed: 23213058
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Oncogene. 2013 Nov 21;32(47):5377-87
pubmed: 23934192
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6
pubmed: 24085845
Cell. 2013 Oct 24;155(3):688-98
pubmed: 24119841
Breast Cancer Res Treat. 2015 Jun;151(3):619-27
pubmed: 26006068
Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6
pubmed: 26047697
Cancer Immunol Res. 2015 Nov;3(11):1257-68
pubmed: 26138335
Cell Host Microbe. 2015 Aug 12;18(2):157-68
pubmed: 26235147
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
J Clin Invest. 2016 Jul 1;126(7):2404-11
pubmed: 27367184
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47
pubmed: 27402769
J Clin Invest. 2016 Aug 1;126(8):3145-57
pubmed: 27454289
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
Cell Rep. 2016 Nov 22;17(9):2367-2381
pubmed: 27880910
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Nature. 2017 Mar 16;543(7645):428-432
pubmed: 28273064
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Int J Mol Sci. 2017 Nov 18;18(11):null
pubmed: 29156566
EMBO J. 2018 Apr 13;37(8):
pubmed: 29496741
Sci Rep. 2018 Mar 20;8(1):4899
pubmed: 29559701
Front Immunol. 2018 Apr 09;9:711
pubmed: 29686682
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Br J Cancer. 2018 Nov;119(11):1392-1400
pubmed: 30425352
EMBO Rep. 2018 Dec;19(12):
pubmed: 30446584
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
Cancer Res. 2019 Feb 1;79(3):452-460
pubmed: 30530501
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5
pubmed: 30540933
J Clin Invest. 2019 Mar 1;129(3):1211-1228
pubmed: 30589644
Sci Rep. 2019 Feb 12;9(1):1853
pubmed: 30755715
Cancer Discov. 2019 May;9(5):646-661
pubmed: 30777870